Intellipharmaceutics International Stock Beta
| IPCIFDelisted Stock | USD 0.04 0.00 0.00% |
Intellipharmaceutics International fundamentals help investors to digest information that contributes to Intellipharmaceutics' financial success or failures. It also enables traders to predict the movement of Intellipharmaceutics OTC Stock. The fundamental analysis module provides a way to measure Intellipharmaceutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intellipharmaceutics otc stock.
Intellipharmaceutics |
Intellipharmaceutics International OTC Stock Beta Analysis
Intellipharmaceutics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Intellipharmaceutics Beta | 1.0 |
Most of Intellipharmaceutics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intellipharmaceutics International is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Intellipharmaceutics International has a Beta of 1.0029. This is 16.62% higher than that of the Pharmaceuticals sector and 27.85% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Intellipharmaceutics Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intellipharmaceutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Intellipharmaceutics could also be used in its relative valuation, which is a method of valuing Intellipharmaceutics by comparing valuation metrics of similar companies.Intellipharmaceutics is currently under evaluation in beta category among its peers.
Intellipharmaceutics returns are very sensitive to returns on the market. As the market goes up or down, Intellipharmaceutics is expected to follow.
Intellipharmaceutics Fundamentals
| Return On Asset | -0.98 | ||||
| Operating Margin | (106.06) % | ||||
| Current Valuation | 4.47 M | ||||
| Shares Outstanding | 33.09 M | ||||
| Shares Owned By Insiders | 1.70 % | ||||
| Shares Owned By Institutions | 11.09 % | ||||
| Number Of Shares Shorted | 714 K | ||||
| Price To Earning | (0.50) X | ||||
| Price To Sales | 66.19 X | ||||
| Gross Profit | 1.4 M | ||||
| EBITDA | (4.45 M) | ||||
| Net Income | (5.15 M) | ||||
| Cash And Equivalents | 79.65 K | ||||
| Total Debt | 2.01 M | ||||
| Debt To Equity | 165.20 % | ||||
| Current Ratio | 0.05 X | ||||
| Book Value Per Share | (0.31) X | ||||
| Cash Flow From Operations | (2.46 M) | ||||
| Short Ratio | 0.39 X | ||||
| Earnings Per Share | (0.16) X | ||||
| Target Price | 25.0 | ||||
| Number Of Employees | 11 | ||||
| Beta | 1.0 | ||||
| Market Capitalization | 2.02 M | ||||
| Total Asset | 2.1 M | ||||
| Retained Earnings | (86.55 M) | ||||
| Working Capital | (5.62 M) | ||||
| Current Asset | 1.41 M | ||||
| Current Liabilities | 7.02 M | ||||
| Z Score | -65.8 | ||||
| Net Asset | 2.1 M |
About Intellipharmaceutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Intellipharmaceutics International's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intellipharmaceutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intellipharmaceutics International based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Intellipharmaceutics OTC Stock
If you are still planning to invest in Intellipharmaceutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intellipharmaceutics' history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |